Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ganglion cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Ganglion cell. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-003079-31 Sponsor Protocol Number: QRK207 Start Date*: 2016-10-20
    Sponsor Name:Quark Pharmaceuticals Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU...
    Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10068242 Nonarteritic anterior ischaemic optic neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000674-31 Sponsor Protocol Number: CFTY720DDE15TS Start Date*: 2012-08-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®
    Medical condition: RNFLT in Patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001200-38 Sponsor Protocol Number: 4C-2011-02 Start Date*: 2012-09-07
    Sponsor Name:BCN Peptides S.A.
    Full Title: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomized controlled trial to assess the efficacy of neuroprotective dru...
    Medical condition: Prevention of neurodegeneration which occurs in Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    15.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016982-26 Sponsor Protocol Number: ST200-ODU-09-01 Start Date*: 2010-11-04
    Sponsor Name:SIGMA-TAU
    Full Title: Neuronal conduction along the visual patways after oral treatment with Acetyl-L-carnitine in patients with Leber’s Hereditary Optic Neuropathy
    Medical condition: Leber’s Hereditary Optic Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061323 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004939-38 Sponsor Protocol Number: IFCT-0801 Start Date*: 2008-10-16
    Sponsor Name:IFCT
    Full Title: Essai randomisé de phase II/III évaluant une stratégie thérapeutique post-opératoire individualisée chez les patients opérés d’un carcinome bronchique non à petites cellules (CBNPC) non épidermoïde...
    Medical condition: L’hypothèse scientifique est que l’utilisation de marqueurs biologiques permettra d’optimiser le traitement adjuvant chez les patients opérés d’un cancer bronchique non à petites cellules.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005113-39 Sponsor Protocol Number: SSP-2 Start Date*: 2013-04-08
    Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis
    Medical condition: Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002515-10 Sponsor Protocol Number: P000053 Start Date*: 2014-07-18
    Sponsor Name:University Medical Center Freiburg
    Full Title: Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003147-29 Sponsor Protocol Number: ACT-01_P2_01 Start Date*: 2020-11-06
    Sponsor Name:ACCURE TX FRANCE SASU
    Full Title: A two-arm randomized double-blind placebo-controlled monocentric study to evaluate the safety and tolerability of ACT-01 compared to placebo in patients with acute optic neuritis
    Medical condition: Subjects from 18 to 60 years old with a diagnosis of a unilateral Acute Optic Neuritis with a demyelinating origin, whose symptoms have appeared in the last 10 days before randomization and whose e...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003677-66 Sponsor Protocol Number: RESTORE Start Date*: 2022-02-14
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis
    Medical condition: Multiple sclerosis (MS) Internuclear ophthalmoparesis (INO)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080865 Multiple sclerosis lesion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005319-30 Sponsor Protocol Number: 217917 Start Date*: 2022-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of imm...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    21.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    20.1 10021881 - Infections and infestations 10030865 Ophthalmic herpes zoster PT
    20.0 10021881 - Infections and infestations 10063491 Herpes zoster oticus PT
    21.1 10021881 - Infections and infestations 10075611 Varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10074297 Herpes zoster cutaneous disseminated PT
    23.1 10021881 - Infections and infestations 10080516 Herpes zoster reactivation PT
    23.1 10021881 - Infections and infestations 10084396 Disseminated varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10072210 Genital herpes zoster PT
    20.1 10021881 - Infections and infestations 10061208 Herpes zoster infection neurological PT
    20.0 10021881 - Infections and infestations 10074259 Herpes zoster meningitis PT
    20.0 10021881 - Infections and infestations 10074248 Herpes zoster meningoencephalitis PT
    20.0 10021881 - Infections and infestations 10074243 Varicella zoster oesophagitis PT
    21.1 10021881 - Infections and infestations 10074254 Varicella zoster pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) EE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003554-23 Sponsor Protocol Number: NL68976.041.19 Start Date*: 2021-12-03
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel lymph node detection in early-stage ORal Cavity squamous cell carcinoma using Magnetic Resonance (MR) lymphogrAphy
    Medical condition: The IMP will be used for the identification of sentinel lymph node(s) in patients with early-stage oral cavity squamous cell carcinoma and a clinically negative neck (T1-3, N0, M0).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10004822 Biopsy of lymph node LLT
    21.0 100000004864 10030961 Oral cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002204-27 Sponsor Protocol Number: GS030_CLIN_001 Start Date*: 2017-12-22
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa
    Medical condition: Retinitis Pigmentosa
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006046-40 Sponsor Protocol Number: 2020/567 Start Date*: 2021-07-02
    Sponsor Name:CHU de Besançon
    Full Title: Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by hypofractionated radiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study.
    Medical condition: cancer du canal anal de stade III
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000395-26 Sponsor Protocol Number: GER-BGT-13-10586 Start Date*: 2015-08-07
    Sponsor Name:Biogen GmbH
    Full Title: A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006291-39 Sponsor Protocol Number: 215ON201 Start Date*: 2012-10-15
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neur...
    Medical condition: Acute Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) CZ (Completed) GB (Completed) HU (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005394-31 Sponsor Protocol Number: 12/0219 Start Date*: 2014-04-01
    Sponsor Name:UCL
    Full Title: MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis
    Medical condition: Mutliple Sclerosis (Secondary Progressive)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002153-11 Sponsor Protocol Number: GS-LHON-CLIN-06 Start Date*: 2018-02-12
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001088-26 Sponsor Protocol Number: MN42928 Start Date*: 2021-12-21
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002715-41 Sponsor Protocol Number: P130934 Start Date*: 2015-08-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: KAWAKINRA study, "A phase IIa multicenter trial to assess the efficacy and safety of Anakinra in patients with intraveinous immunoglobulin-resistant Kawasaki disease"
    Medical condition: Anakinra treatment is expected to reduce the early and long term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002895-42 Sponsor Protocol Number: GITS2013_4.0 Start Date*: 2013-10-10
    Sponsor Name:Region Västerbotten
    Full Title: Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma (GITS...
    Medical condition: Glaucoma, open-angle and PEX glaucoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10030856 Open-angle glaucoma LLT
    20.0 100000004853 10037118 Pseudoexfoliation glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:51:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA